Recombinant Antibodies for IVD and Therapeutics
The recombinant antibody market is quickly expanding as researchers and industry leaders look for monoclonal antibody alternatives. Consistency, reproducibility, and global manufacturing strategies are driving the interest in recombinant, animal-free options. These recombinant antibodies have inherent advantages and disadvantages.
Join Rockland's Product Manager, Todd Giardiello, and our Chief Science Officer, Dr. Carl Ascoli as they discuss this and much more.
Accept Quote